Diabetes and advanced glycation endproducts

Journal of Internal Medicine

Volumn 251, Issue 2, 2002, Pages 87-101

  Vlassara, H ^a   Palace, M R ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; OPD 9195; THIAZOLIDINE DERIVATIVE;

AGING; ATHEROSCLEROSIS; BIOLOGY; CELL INTERACTION; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; EYE DISEASE; GENETIC ANALYSIS; GLYCATION; HUMAN; KIDNEY CLEARANCE; KIDNEY DISEASE; NEUROLOGIC DISEASE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; TOXICITY;

ANIMALS; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY GLOMERULUS; RECEPTORS, IMMUNOLOGIC;

EID: 0036167208     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2002.00932.x     Document Type: Review

References (150)

1. Diabetes mellitus and its degenerative complications: Prospective study of 4400 patients observed between 1947 and 1973
2. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus
3. Biochemical and molecular mechanisms in the development of diabetic vascular complications
4. Progression of incipient diabetic retinopathy during good glycemic control
5. Advanced glycosylation end products in patients with diabetic nephropathy
6. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure
7. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes
8. Inhibition of heparin-catalyzed human antithrombin III activity by nonenzymatic glycosylation. Possible role in fibrin deposition in diabetes
9. Glycation of amino groups in protein. Studies on the specificity of modification of RNase by glucose
10. The effect of nonenzymatic glucosylation on the binding of the main noncollagenous NC1 domain to type IV collagen
11. Advanced glycation end products contribute to amyloidosis in Alzheimer disease
12. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor
13. Lipi advanced glycosylation: Pathway for lipid oxidation in vivo
14. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insuficiency
15. Atherogenesis and advanced glycation: Promotion, progression, and prevention. Annals of the New York Academy of Sciences 1997
16. Elevated AGE-modified ApoB in the sera of euglycemic, normolipidemic patients with atherosclerosis
17. End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen
18. Nonenzymatic browning in vivo: Possible process for aging of long-lived proteins
19. Collagen aging in vitro by nonenzymatic glycosylation and browning
20. The lens: Development proteins, metabolism and cataract
21. Diabetic cataract formation: Potential role of glycosylation of lens crystallins
22. The browning reaction of proteins with glucose
23. Immunochemical evidence for increased formation of advanced glycation end products and inhibition by amino-guanidine in diabetic rat lenses
24. Advanced glycation endproducts in vitreous: Structural and functional implications for diabetic vitreopathy
25. Structural and functional changes of laminin and type IV collagen after nonenzymatic glycation
26. Degradation of glomerular basement membrane in diabetes. I. Susceptibility of diabetic and nondiabetic basement membrane to proteolytic degradation of isolated glomeruli
27. Glycation of collagen: The basis of its central role in the late complications of aging and diabetes
28. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen
29. Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina
30. Decreased interaction of fibronectin, type IV collagen, and heparin due to nonenzymatic glycation. Implications for diabetes mellitus
31. Molecular mechanisms in basement membrane complications of diabetes. Alterations in heparin, laminin, and type IV collagen association
32. Modification of DNA by reducing sugars: A possible mechanism for nucleic acid aging and age-related dysfunction in gene expression
33. Elevated glucose 6-phosphate levels are associated with plasmid mutations in vivo
34. Modification of DNA by glucose 6-phosphate induces DNA rearrangements in an Escherichia coli plasmid
35. ADP-ribose in glycation and glycoxidation reactions
36. Glycation and glycoxidation of histones by ADP-ribose
37. Histones from diabetic rats contain increased levels of advanced glycation end products
38. Malformations in infants of diabetic mothers
39. Malformations in infants of diabetic mothers occur before the seventh gestational week. Implications for treatment
40. Lack of relation of increased malformation rates in infants of diabetic mothers to glycemic control during organogenesis
41. Nutritional consequences of the Maillard reaction. Amino acid availability from fructose-leucine and fructose-tryptophan in the rat
42. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy
43. Restriction of AGE content of food without lowering protein intake prevents diabetic nephropathy in mice
44. Lowering of diet-derived advanced glycation endproducts reduces postangioplasty restenosis in apo-E deficient mice: A new solution? Abstract
45. Suppression of atherosclerotic lesions by dietary restriction of advanced glycation endproducts in diabetic Apo-E deficient C57BL/6J mice
46. Tobacco smoke is a source of toxic reactive glycation products
47. Tobacco smoke is a source of advanced glycation endproducts (AGEs): Possible role in the accelerated vascular disease of smokers
48. Cigarette smoke-derived advanced glycation endproducts: Role in cataractogenesis and atherosclerosis
49. Pathogenic effects of advanced glycosylation endproducts: Biochemical, biologic, and clinical implications for diabetes and aging
50. Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors
51. Isolation of surface binding protein specific for advanced glycosylation end products from mouse macrophage-derived cell line RAW 264.7
52. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: Relationship to macrophage scavenger receptor for glucose modified proteins
53. Molecular identity and cellular distribution of advanced glycation endproduct receptors. Relationship of p60 to OST-48 and 80K-H membrane proteins
54. Identification of p90, a prominent tyrosine-phosphorylated protein in fibroblast growth factor stimulated cells, as 80KH
55. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): A new member of the AGE-receptor complex
56. The advanced glycation endproduct (AGE) receptor complex: Characterisation in micro and macrovascular endothelium
57. Cachectin/TNF and IL-1 induced by glucose-modified proteins: Role in normal tissue remodeling
58. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins
59. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis
60. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating age proteins
61. Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins
62. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction
63. CD36, a member of class B scavenger receptor family, as a receptor for advanced glycation end products
64. Human blood-brain barrier receptors for Ab 1-40
65. Insulin enhances macrophage scavenger receptor-mediated endocytic uptake of advanced glycation end products
66. Advanced glycation endproducts and their recognition by macrophage and macrophage-derived cells
67. Pharmacological aspects and therapeutic applications of lysozymes
68. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif
69. Depletion of reactive advanced glycation endproducts from diabetic uremic sera by a lysozyme-linked matrix
70. Lysozyme enhances renal excretion of advanced glycation endproducts in vivo and suppresses adverse AGE-medicated cellular effects in vitro: A potential AGE sequestration therapy for diabetic nephropathy?
71. In vivo treatment of diabetic mice (NOD and db/db) with lysozyme (LZ) enhances renal clearance of glycoxidation products and prevents albuminuria
72. Lysozyme (LZ) is secreted by mesangial cells and inhibits glycoxidation-dependent glomerular gene dysregulation in vitro and in vivo: A novel defense mechanism against diabetic nephropathy
73. Advanced glycation endproducts (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats
74. Specific macrophage receptor activity for advanced glycosylation end products inversely correlates with insulin levels in vivo
75. Macrophage/monocyte receptor for nonenzymatically glycosylated protein is upregulated by cachectin/tumor necrosis factor
76. Advanced non-enzymatic tissue glycosylation: Mechanisms implicated in the complications associated with aging
77. Characterization of a solubilized cell surface binding protein on macrophages specific for proteins modified nonenzymatically by advanced glycosylated end products
78. Advanced glycation end product receptor interactions on microvascular cells occur within caveolin-rich membrane domains
79. Accelerated diabetic glomerulopathy in Galectin-3/AGE-receptor-3 knockout mice
80. Differential expression of renal AGE-receptor genes in NOD mice: Possible role in NOD diabetic renal disease
81. Low expression of AGE-receptor-1 in NOD mouse mesangial cells: Possible link to diabetic nephropathy
82. Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear AGE-receptor-1 and elevated serum AGE
83. Mononuclear (MN) cell AGE receptor-1 (AGE-R1) mRNA expression and its relationship to diabetic complications
84. The human LGALS3 (Gelectin-3) gene: Determination of the gene structure and functional characterization of the promoter
85. Isolation of cDNAs encoding a substate for protein kinase C: Nucleotide sesquence and chromosomal mapping of the gene for a human 80K-H protein
86. Genome organization of human 48-kDa oligosaccharryltranferase (DDOST)
87. Polymorphism screening of four genes encoding advanced glycation end product putative receptors: Association study with nephropathy in Type 1 diabetes patients
88. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene
89. Endocytosis by retinal vascular endothelial cells increases in early diabetes: A quantitative EM study in STZ-diabetic rats
90. Increased endocytosis of retinal vascular endothelial cells grown in hyperglycemia is modulated by inhibitors of non-enzymatic glycosylation
91. Recent progress in advanced glycation end products and diabetic complications
92. Beta 2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis
93. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1
94. Possible significance of advanced glycation end products in serum in end-stage renal disease and in late complications of diabetes
95. Overexpression of glyoxalase-1 in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis
96. Clinical characteristics in diabetic stroke patients
97. Diabetes and coronary artery disease: What a coincidence?
98. Diabetes as an atherogenic factor
99. The pathogenesis of atherosclerosis: A perspective for the 1990s
100. Altered metabolism (in vivo and in vitro) of plasma lipoproteins after selective chemical modification of lysine residues of the apoprotein B
101. Inhibition of lipoprotein binding to surface receptors of fibroblasts following selective modification of arginyl residues in apoprotein B
102. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoproteins producing massive cholesterol deposition
103. Factors regulating the activities of the low density lipoprotein receptor and the scavenger receptor on human monocytes macrophages
104. Immunological evidence for the presence of advanced glycosylation endproducts products in atherosclerotic lesions of euglycemic rabbits
105. Immunohistochemical and ultrastructural detection of advanced glycation endproducts in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody
106. Immunohistochemical localization of advanced glycosylation endproducts (AGEs) in coronary atheroma and cardiac tissue in diabetes
107. Pathobiology of the heart in experimental diabetes: Immunolocalization of lipoproteins, immunoglobulin G, and advanced glycation endproducts proteins in diabetic and/or hyperlipidemic hamster
108. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients
109. Extra- and intracellular localization of advanced glycation end-products in human atherosclerotic lesions
110. Increased macrophage uptake of irreversibly glycated albumin modified-low density lipoproteins of normal and diabetic subjects is mediated by non-saturable mechanisms
111. Advanced glycation end products in human penis: Elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS
112. Advanced glycosylation products quench nitric oxide and mediate defective endothelium dependent vasodilatation in experimental diabetes
113. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and ageing complications
114. Endothelium and regulation of coagulation
115. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits
116. Capillary number and percentage closed in human diabetic sural nerve
117. Diabetic neuropathies
118. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin induced rat
119. The role of endothelium in the pathogenesis of diabetic microangiopathy
120. Quantitative study on glomerular ultrastructure in type I diabetes with incipient nephropathy
121. Renal function changes in diabetes
122. Reaction of advanced glycation endproducts with renal tissue from normal and streptozotocin induced diabetic rats. An ultrastructural study using colloidal gold cytochemistry
123. Renal fate of circulating advanced glycation end products (AGE): Evidence for reabsorption and catabolism of AGE peptides by renal proximal tubular cells
124. Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy
125. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism
126. Effects of aminoguanidine on serum advanced glycation endproducts, urinary albilmin excretion, mesangial expansion, and glomerular basement membrane thickening in Otsuka Long-Evans Tokushima fatty rats
127. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
128. The relationship of glycaemic level to advanced glycation end-product (AGE) accumulation and retinal pathology in the spontaneous diabetic hamster
129. Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice
130. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy
131. Pharmacological inhibition of diabetic retinopathy
132. Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats
133. Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model
134. Aminoguanidine prevents diabetes- induced arterial wall protein cross-linking
135. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis
136. Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit
137. Advanced glycosylation endproducts in experimental murine diabetic nephropathy: Effect of islet isografting and of aminoguanidine
138. Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus
139. Aminoguanidine prevents regional blood flow increases in streptozotocin-diabetic rats
140. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin induced rat
141. Mechanistic studies of advanced glycosylation endproduct inhibition by aminoguanidine
142. The effect of aminoguanidine on the blood retinal barrier in streptozotocin induced diabetic rats
143. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation
144. Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix
145. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo
146. Breaking the curse of the AGEs
147. Breakers of advanced glycation end products restore large artery properties in experimental diabetes